A Monoclonal Antibody with a High Affinity for Ricin Isoforms D and E Provides Strong Protection against Ricin Poisoning
Toxins · 2024
DOI: 10.3390/toxins16100412 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, 2024. Verfasst von Loïs Lequesne und 11 weiteren Autor:innen. Beteiligte Einrichtung: Département Médicaments et Technologies pour la Santé (DMTS), SPI, Université Paris Saclay, CEA, INRAE, 91191 Gif-sur-Yvette, France. Hauptthemen laut MEDLINE: Ricin, Antibodies, Monoclonal, Mice, Inbred BALB C. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agence Nationale de la Recherche, French interministerial program for research and development in the fight against CBRN, French General Secretariat for Defense and National Security.
Abstract (Originalsprache)
Ricin is a highly potent toxin that has been used in various attempts at bioterrorism worldwide. Although a vaccine for preventing ricin poisoning (RiVax™) is in clinical development, there are currently no commercially available prophylaxis or treatments for ricin intoxication. Numerous studies have highlighted the potential of passive immunotherapy using anti-ricin monoclonal antibodies (mAbs) and have shown promising results in preclinical models. In this article, we describe the neutralizing and protective efficacy of a new generation of high-affinity anti-ricin mAbs, which bind and neutralize very efficiently both ricin isoforms D and E in vitro through cytotoxicity cell assays. In vivo, protection assay revealed that one of these mAbs (RicE5) conferred over 90% survival in a murine model challenged intranasally with a 5 LD50 of ricin and treated by intravenous administration of the mAbs 6 h post-intoxication. Notably, a 35% survival rate was observed even when treatment was administered 24 h post-exposure. Moreover, all surviving mice exhibited long-term immunity to high ricin doses. These findings offer promising results for the clinical development of a therapeutic candidate against ricin intoxication and may also pave the way for novel vaccination strategies against ricin or other toxins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Département Médicaments et Technologies pour la Santé (DMTS), SPI, Université Paris Saclay, CEA, INRAE, 91191 Gif-sur-Yvette, France.
- Microbiology and Infectious Diseases Department, French Armed Forces Biomedical Research Institute, 91220 Brétigny-sur-Orge, France.
ORCID-Profile: Loïs Lequesne, Camille Kropp, Arnaud Avril, François Becher, Maria Lucia Orsini Delgado, Stéphanie Simon
Förderung
- Agence Nationale de la Recherche
- French interministerial program for research and development in the fight against CBRN
- French General Secretariat for Defense and National Security
- French National Research Agency in the context of the Franco-German project PLANT
Zitieren
APA
Lequesne, L., Dano, J., Rouaix, A., Kropp, C., Plaisance, M., Gelhaye, S., Lequesne, M. L., Piquet, P., Avril, A., Becher, F., Orsini Delgado, M. L., & Simon, S. (2024). A Monoclonal Antibody with a High Affinity for Ricin Isoforms D and E Provides Strong Protection against Ricin Poisoning. Toxins. https://doi.org/10.3390/toxins16100412
Vancouver
Lequesne L, Dano J, Rouaix A, Kropp C, Plaisance M, Gelhaye S, et al. A Monoclonal Antibody with a High Affinity for Ricin Isoforms D and E Provides Strong Protection against Ricin Poisoning. Toxins. 2024. doi:10.3390/toxins16100412
BibTeX
@article{Lequesne2024,
author = {Lequesne, Loïs and Dano, Julie and Rouaix, Audrey and Kropp, Camille and Plaisance, Marc and Gelhaye, Stéphanie and Lequesne, Marie-Lou and Piquet, Paloma and Avril, Arnaud and Becher, François and Orsini Delgado, Maria Lucia and Simon, Stéphanie},
title = {A Monoclonal Antibody with a High Affinity for Ricin Isoforms D and E Provides Strong Protection against Ricin Poisoning},
journal = {Toxins},
year = {2024},
doi = {10.3390/toxins16100412}
}
EUVIMED